LPAL2 and cardiomyopathy: This observation, together with the finding that decreased ApoA-l levels in the general population are associated with an increased risk of mortality from cardiomyopathy and heart failure [20,21], led us to compare serum Apo-AI levels in FA with a large cohort of control subjects.